Navigation Links
Common transplant drug inhibits breast cancer growth, UNC laboratory study shows
Date:5/26/2011

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

Nancy Klauber-DeMore, MD, associate professor of surgery, said, " We now have a rationale for performing human clinical trials to determine if Tacrolimus reduces breast cancer growth in humans. Since Tacrolimus is already an FDA-approved drug, the safety and toxicity profile is known, which means that Tacrolimus could potentially go directly into a later stage clinical trial."

Klauber-DeMore is a member of UNC Lineberger Comprehensive Cancer Center and co-founder and Chief Scientific Officer of Enci Therapeutics, Inc., a UNC spin-off biotech company.

Tacrolimus is used to prevent rejection (when a person's immune system attacks of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. Tacrolimus is in a class of medications called immunosuppressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. Tacrolimus does this by binding to and inactivating a protein called calcineurin in immune cells.

Although preventing organ transplant rejection and inhibiting cancer growth may seem unrelated, the team realized that activating calcineurin is a common pathway that stimulates both the immune system and the growth of new blood vessels to tumors. Blocking blood vessel growth to tumors is a therapeutic strategy to inhibit tumor growth.

Klauber-DeMore's group had previously discovered that a protein called SFRP2 stimulates blood vessel growth and is expressed in human breast cancers. While investigating the mechanism through which SFRP2 stimulates blood vessel growth, they found that SFRP2 activates calcineurin in blood vessel cells. Based on this mechanism, Klauber-DeMore thought tha
'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-7834
University of North Carolina School of Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Adapting to clogged airways makes common pathogen resist powerful drugs
2. A common cholesterol drug fights cataracts, too
3. U.S. National Guard Connects Nationwide with Desktop Alert's Command and Control Mass Notification Systems and Common Alerting Protocol (CAP)
4. US21, Inc. is Granted a Wholesale Distributor Permit from the Commonwealth of Virginia Board of Pharmacy
5. New therapeutic target for most common solid cancer in childhood?
6. Migraine More Common in Women with MS
7. Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis
8. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
9. Six "Common Sense" Points Not Included In The Health Care Discussion? Should They Be?
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Commonwealth Leverage Group and Helium Interactive Form HIE Go-To-Market Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Gables, FL (PRWEB) December 22, 2014 Coral ... lice removal service , Lice Troopers, with its new clinic ... in southern Florida, takes the hassle out of dealing with ... services in one of their two salon clinic locations in ... or other location. , The decision to expand developed naturally ...
(Date:12/22/2014)... York (PRWEB) December 22, 2014 The holidays ... staple of the season. Many may be thinking about how ... span of a few weeks. Health Republic Insurance of New ... Registered Dietitian, Andrea Chernus, to provide some smart ideas to ... stay healthy. , 1)    Avoid arriving at a holiday gathering over-hungry ...
(Date:12/22/2014)... Physicians in China are most eagerly awaiting ... non-Hodgkin’s lymphoma (NHL), according to a new report from ... firm. MabThera is the only biologic available to treat ... of NHL. , According to Kantar Health’s report, “Biosimilars ... NHL in China has been growing and is expected ...
(Date:12/22/2014)... 2014 Only weeks following the announcement ... cities to have a battery manufacturer create 29 well-paying ... http://www.talklocal.com ) is launching in Henderson to deliver ... “A strong manufacturing sector is going to build a ... explained, “and TalkLocal works with small businesses that rely ...
(Date:12/22/2014)... Pasadena sleep apnea dentist, Dr. Marine ... drivers are 15 times more likely to cause deadly ... experts believe that sleep-deprived drivers may be just as ... of Americans may be sleep-deprived without even knowing it. ... 18 million Americans have sleep apnea, but as many ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2
... , CLEVELAND, Dec. 8 Agilysys, ... information technology and hospitality software solutions, announced today that Summa ... of software solutions to streamline efficiency and control costs in ... use Eatec® Solutions by Agilysys, an inventory and procurement system; ...
... , LAS VEGAS, Dec. 8 ... Glen Tullman will host a webcast today, broadcasted live from the ... innovations: Allscripts Professional(TM) EHR 9.0 , a breakthrough in user ... physician groups; and Allscripts Remote (TM) for BlackBerry ® ...
... , ... leveraging Ifbyphone,s Virtual Call Center software and bringing ... over 50% while also integrating interactive voice response (IVR) technology ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20091020/LA94596LOGO ) , DiabetesAmerica looked to ...
... HUNTINGTON BEACH, California and AMSTERDAM, December 8 ... that,it will be presenting six studies focusing on MammaPrint(R) at ... premiere conferences in,breast cancer research worldwide. The SABCS will take ... San Antonio, Texas, USA. , Agendia,s ...
... SAN FRANCISCO, Calif., Dec. 8 Anesiva, Inc. (Nasdaq: ... received a letter from The NASDAQ Stock Market ("Nasdaq") stating ... of Publicly Held Shares (MVPHS) of $5,000,000 during the last ... in compliance with Listing Rule 5450(b)(1)(C). The notification letter has ...
... ... STRM ) a leading provider of document workflow solutions ... selected the Company,s enterprise technology to improve quality and operating ... patient medical record across their healthcare enterprise. The implementation ...
Cached Medicine News:Health News:Summa Health System Selects Software Solution Suite from Agilysys 2Health News:Summa Health System Selects Software Solution Suite from Agilysys 3Health News:Allscripts Launches New Innovations in Live Event 2Health News:Allscripts Launches New Innovations in Live Event 3Health News:Allscripts Launches New Innovations in Live Event 4Health News:Allscripts Launches New Innovations in Live Event 5Health News:Allscripts Launches New Innovations in Live Event 6Health News:Ifbyphone's Virtual Call Center Software Saves DiabetesAmerica Over $240,000 Per Year 2Health News:Ifbyphone's Virtual Call Center Software Saves DiabetesAmerica Over $240,000 Per Year 3Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 2Health News:Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium 3Health News:Anesiva Receives NASDAQ Listing Compliance Notice 2Health News:Anesiva Receives NASDAQ Listing Compliance Notice 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 2Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 3Health News:Moses Cone Health System Selects Streamline Health to Enhance the Electronic Medical Record 4
(Date:12/19/2014)... IRVINE, Calif. , Dec. 19, 2014 /PRNewswire/ ... today that Siddhartha Kadia, Ph.D. has joined the ... and Chief Executive Officer and a director of ... high-precision laboratory testing, evaluation and analytical services to ... Prior to joining Evans Analytical Group, ...
(Date:12/19/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ADMD), ... the development of brachytherapy devices and medical isotopes ... a Life Sciences Discovery Fund (LSDF) Proof of ... is the commercialization partner.  The award was made ... titled "Optimized Injectable Radiogels for High-dose Therapy of ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... 2012  Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: ... of an Investigational New Drug application (IND)  with the U.S. ... (V600E) kinase inhibitor.  The IND filing ... as evidenced by data revealed in recent publications in ...
... - Atu027, a First in Class RNAi Therapy, Demonstrates Potential ... Biomarker Identified Silence Therapeutics to Announce New Data ... 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: ... (RNAi) therapeutics company, today announces that top line data from ...
Cached Medicine Technology:Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 2Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 3Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 4Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
Open armhole design with Velcro release enables removal without compromising sterile field. Loops attached at shoulders for proper hanging & storage...
The most comfortable and easy to use apron in the industry. This front protection apron comes with a fully adjustable snap-on 5" orthopedic belt to relieve weight off your shoulders. Velcro strap acr...
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
Medicine Products: